RXST RxSight (RXST) Insider Trading, Ownership & Congress Trades
Medical Devices · Ophthalmic goods · CIK 0001111485
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
96
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $152.6K priced
What the filings say about RXST
Insiders, 180 days
-$118.0K net sold
4 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$193.7K
5 notices
RxSight insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, RxSight, Inc. insiders sold a net $118.0K of stock across 157 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 8 earlier Form 4 trades (code P or S) here by this insider (2 buys, 6 sales), the last on May 3, 2024.
- -15.9% median (-15.9% mean) 90-day return after 2 previous buys.
- The trade is 7.1% of the 71,775 shares held after it.
- 3 other insiders sold within 30 days.
- 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Kurtz Ronald M MD sold about $35.5K of RXST on Sep 2, 2026, the largest insider sale at the company since 2025; 3 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 31.0% of the 25,049 shares held after it.
- 3 other insiders sold within 30 days.
- 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Wilterding Mark sold about $54.0K of RXST on Sep 2, 2026, the largest insider sale at the company since 2025; 3 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.Context
- 61 earlier Form 4 trades (code P or S) here by this insider (2 buys, 59 sales), the last on Nov 29, 2024.
- The trade is 2.5% of the 81,509 shares held after it.
- 3 other insiders sold within 30 days.
- 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Goldshleger Ilya sold about $14.2K of RXST on Sep 2, 2026, the largest insider sale at the company since 2025; 3 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (6 buys, 6 sales), the last on Feb 1, 2024.
- -24.3% median (-19.9% mean) 90-day return after 5 previous buys.
- The trade is 1.0% of the 200,348 shares held after it.
- 3 other insiders sold within 30 days.
- 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See remarks Weinberg Eric sold about $14.2K of RXST on Sep 2, 2026, the largest insider sale at the company since 2025; 3 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 28.2% of the 24,793 shares held after it.
- No other insider sold within 30 days.
- 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Fountain Tamara sold about $180.0K of RXST on Mar 12, 2025; 96 funds added in the latest 13F quarter.157 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$118.0K over 180 days
-$118.0K over 90 days
more than 53% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
96 funds bought in last quarter
more than 63% of Medical Devices
Revenue
-3.9% year over year
below 82% of Medical Devices
Margin
-29.0% net margin
below 59% of Medical Devices
Buybacks
no share repurchases reported
Short interest
12.1% of the float short (float per yahoo 2026-10-26) · 4.6 days to cover · settled 2026-09-30
more than 89% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch RXST
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-40.5%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns RXST: institutional holders (13F)
13F holdings, latest reported quarter
5,790,408 sh
$27.9M
3,030,287 sh
$14.6M
2,055,000 sh
$9.9M
2,000,060 sh
$9.6M
1,985,215 sh
$9.6M
Congress trades in RXST
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
RXST planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Goldshleger Ilya
Filed 2026-09-02
$14.2K
Kurtz Ronald M MD
Filed 2026-09-02
$35.5K
Weinberg Eric
Filed 2026-09-02
$14.2K
Wilterding Mark
Filed 2026-09-02
$54.0K
RAYMOND W COHEN
Filed 2026-08-18
$75.7K
RXST mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
GRANDEUR PEAK GLOBAL CONTRARIAN FUND
$990.6K position · as of 2026-07-31
0.7%
GRANDEUR PEAK GLOBAL OPPORTUNITIES FUND
$1.2M position · as of 2026-07-31
0.3%
Brown Capital Management Small Company Fund
$800.0K position · as of 2026-06-30
0.2%
Ultra-Small Company Market Fund
$289.2K position · as of 2026-06-30
0.2%
Federated Hermes MDT Small Cap Core Fund
$3.9M position · as of 2026-07-31
0.2%
Federated Hermes MDT Small Cap Growth Fund
$1.3M position · as of 2026-07-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Not applicable
0 active
What changed recently
Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (L
2026-10-17 · Enrolling By Invitation → Completed
,
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.7M
-$2.2M
$2.5M
-7%
-24%
2024
$7.0M
$5.1M
$5.8M
+206%
-24%
2023
$3.1M
$11.8M
$1.8M
+258%
-28%
2022
$1.0M
$1.2M
$649.4K
+13%
-23%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $118.0K sold by insiders over 180 days, 96 funds added last quarter, $193.7K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
RXST financials
Revenue growth
-3.9%
XBRL, annual
Net margin
-29.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$127.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM RXST
| FY Dec 2025 | $134.5M |
| FY Dec 2024 | $139.9M |
| FY Dec 2023 | $89.1M |
| FY Dec 2022 | $49.0M |
| FY Dec 2021 | $22.6M |
| Jun 2026 | $33.7M |
| Mar 2026 | $30.9M |
| Dec 2025 | $32.6M |
| Sep 2025 | $30.3M |
| Jun 2025 | $33.6M |
| Mar 2025 | $37.9M |
| Dec 2024 | $40.2M |
| Sep 2024 | $35.3M |
At each fiscal year end
Single quarter
Net margin, TTM
-6.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM RXST
| FY Dec 2025 | -0.0% |
| FY Dec 2024 | -0.0% |
| FY Dec 2023 | -0.0% |
| FY Dec 2022 | -0.0% |
| FY Dec 2021 | -215.5% |
| Jun 2026 | -35.9% |
| Mar 2026 | -51.4% |
| Dec 2025 | +91.4% |
| Sep 2025 | -32.4% |
| Jun 2025 | -35.0% |
| Mar 2025 | -21.6% |
| Dec 2024 | +53.5% |
| Sep 2024 | -17.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$27.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM RXST
| FY Dec 2025 | -$19.3M |
| FY Dec 2024 | -$22.4M |
| FY Dec 2023 | -$46.4M |
| FY Dec 2022 | -$61.2M |
| FY Dec 2021 | -$46.6M |
| Jun 2026 | -$11.5M |
| Mar 2026 | -$11.7M |
| Dec 2025 | -$2.3M |
| Sep 2025 | -$1.8M |
| Jun 2025 | -$5.9M |
| Mar 2025 | -$9.4M |
| Dec 2024 | -$5.1M |
| Sep 2024 | -$453.0K |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2023-12-31 (30 months older than the period end); equity 2026-06-30
Debt to equity RXST
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.45x |
| FY Dec 2021 | 0.29x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt RXST
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -1.47x |
| FY Dec 2021 | -1.12x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-3.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity RXST
| FY Dec 2025 | -0.0% |
| FY Dec 2024 | -0.0% |
| FY Dec 2023 | -0.0% |
| FY Dec 2022 | -0.0% |
| FY Dec 2021 | n/a |
| Jun 2026 | -3.0% |
| Mar 2026 | -2.8% |
| Dec 2025 | -0.0% |
| Sep 2025 | -3.0% |
| Jun 2025 | -1.7% |
| Mar 2025 | +0.4% |
| Dec 2024 | -0.0% |
| Sep 2024 | +8.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-2.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets RXST
| FY Dec 2025 | -0.0% |
| FY Dec 2024 | -0.0% |
| FY Dec 2023 | -0.0% |
| FY Dec 2022 | -0.0% |
| FY Dec 2021 | -33.2% |
| Jun 2026 | -2.4% |
| Mar 2026 | -2.5% |
| Dec 2025 | -0.0% |
| Sep 2025 | -2.7% |
| Jun 2025 | -1.6% |
| Mar 2025 | +0.4% |
| Dec 2024 | -0.0% |
| Sep 2024 | +7.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital RXST
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-19.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed RXST
| FY Dec 2025 | -16.7% |
| FY Dec 2024 | -16.2% |
| FY Dec 2023 | -34.0% |
| FY Dec 2022 | -40.3% |
| FY Dec 2021 | -39.0% |
| Jun 2026 | -19.7% |
| Mar 2026 | -19.5% |
| Dec 2025 | -16.7% |
| Sep 2025 | -15.8% |
| Jun 2025 | -14.8% |
| Mar 2025 | -16.2% |
| Dec 2024 | -16.2% |
| Sep 2024 | -17.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing RXST
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$195.4M
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term debt only, 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
Enterprise value RXST
| FY Dec 2025 | $408.5M |
| FY Dec 2024 | $1.4B |
| FY Dec 2023 | $1.4B |
| FY Dec 2022 | $379.6M |
| FY Dec 2021 | $323.1M |
| Jun 2026 | $186.2M |
| Mar 2026 | $236.6M |
| Dec 2025 | $408.5M |
| Sep 2025 | $338.2M |
| Jun 2025 | $487.9M |
| Mar 2025 | $994.4M |
| Dec 2024 | $1.4B |
| Sep 2024 | $1.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-13.0%
TTM free cash flow over market value at close 2026-10-23
FCF yield RXST
| FY Dec 2025 | -4.5% |
| FY Dec 2024 | -1.6% |
| FY Dec 2023 | -3.2% |
| FY Dec 2022 | -17.4% |
| FY Dec 2021 | -15.2% |
| Jun 2026 | -13.6% |
| Mar 2026 | -8.5% |
| Dec 2025 | -4.5% |
| Sep 2025 | -6.0% |
| Jun 2025 | -4.0% |
| Mar 2025 | -2.0% |
| Dec 2024 | -1.6% |
| Sep 2024 | -1.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing RXST
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $134.5M | $139.9M | $89.1M | $49.0M |
| Gross profit | $103.0M | $98.9M | $53.8M | $21.3M |
| Operating income | -$48.2M | -$36.9M | -$50.1M | -$63.3M |
| Net income | -$39 | -$28 | -$49 | -$67 |
| EPS (diluted) | -0.95 | -0.71 | n/a | n/a |
| Operating cash flow | -$15.5M | -$16.9M | -$41.6M | -$58.9M |
| Cash | $19.9M | $16.7M | $9.7M | $11.8M |
| Long-term debt | n/a | n/a | $0 | $40.2M |
SEC XBRL, fiscal years, as known on 2026-10-28
RXST Stock Sonar score 6/7 axes
Find similar shapesCompareRXST ranks highest on financial health (99th percentile) and institutional and government (63rd), and lowest on growth (18th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
RXST filings, in plain words
Are RxSight insiders buying or selling RXST?
In the 180 days to 2026-10-28, RxSight insiders were net sellers, a net $118.0K across purchases and sales reported on Form 4, by 4 sellers.
Are there planned insider sales of RXST?
Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $193.7K of stock; the latest, by Goldshleger Ilya, was filed 2026-09-02.
Read the full summary
In the 180 days to 2026-10-28, RxSight insiders were net sellers of RXST, a net $118.0K across purchases and sales reported on Form 4 by 4 sellers. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $193.7K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
